Shaji Kumar, MD, provides perspective on the role of anti-CD38 antibodies changing multiple myeloma

Shaji Kumar, MDПодробнее

Shaji Kumar on the Changing Immunotherapy Landscape in MyelomaПодробнее

HealthTree Podcast for Multiple Myeloma: Dr. Shaji Kumar, Mayo ClinicПодробнее

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma todayПодробнее

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed MyelomaПодробнее

First-in-human study of TAK-169 in R/R MMПодробнее

Shaji Kumar, MD, shares the take home message for physicians treating 1st line multiple myelomaПодробнее

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MDПодробнее

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myelomaПодробнее

Dr Shaji Kumar Discusses Biological Foundations of New Multiple Myeloma ResearchПодробнее

Dr. Shaji Kumar on MRD in Multiple MyelomaПодробнее

Phase I study of TNB-383B in R/R multiple myelomaПодробнее

Dr. Shaji Kumar on Upfront Combination Treatments in Multiple MyelomaПодробнее

Dr. Shaji Kumar on New Criteria for Response and MRD Assessment in Multiple MyelomaПодробнее

Shaji Kumar, MD, discusses excitement about bispecific antibodies in multiple myelomaПодробнее

Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple MyelomaПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myelomaПодробнее

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one dayПодробнее